Viatris (VTRS) Other Operating Expenses (2019 - 2026)
Viatris' (VTRS) quarterly Other Operating Expenses came in at -$53.5 million in Q1 2026, down 172.79% year-on-year from $73.5 million in Q1 2025, and down 1825.81% quarter-over-quarter from $3.1 million in Q4 2025.
Viatris (VTRS) Other Operating Expenses (2019 - 2026) Analysis & Trends
Viatris' Other Operating Expenses history runs 8 years deep, the most recent figure standing at -$53.5 million for Q1 2026.
- On a quarterly basis, Other Operating Expenses fell 172.79% year-over-year to -$53.5 million in Q1 2026; TTM through Mar 2026 was -$58.5 million, a 70.84% increase from a year earlier, with the FY2025 full-year figure at $68.5 million, up 119.52% from the prior year.
- Other Operating Expenses declined to -$53.5 million in Q1 2026 per VTRS's latest filing, from $3.1 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $73.5 million in Q1 2025 and bottomed at -$148.1 million in Q4 2023.
- The 5-year median for Other Operating Expenses is -$6.2 million (2022), against an average of -$26.6 million.
- Across the five-year window, Other Operating Expenses jumped 569.23% in 2023 and sank 12700.0% in 2024, its largest moves.
- Year by year, Other Operating Expenses stood at $8.8 million in 2022, then tumbled by 1782.95% to -$148.1 million in 2023, then climbed by 24.65% to -$111.6 million in 2024, then surged by 102.78% to $3.1 million in 2025, then sank by 1825.81% to -$53.5 million in 2026.
- Per Business Quant, the three latest VTRS Other Operating Expenses figures stand at -$53.5 million (Q1 2026), $3.1 million (Q4 2025), and -$55.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.50 Mn |
| Dec 31, 2025 | 3.10 Mn |
| Sep 30, 2025 | -55.70 Mn |
| Jun 30, 2025 | 47.60 Mn |
| Mar 31, 2025 | 73.50 Mn |
| Dec 31, 2024 | -111.60 Mn |
| Sep 30, 2024 | -31.50 Mn |
| Jun 30, 2024 | -131.00 Mn |
| Mar 31, 2024 | -76.80 Mn |
| Dec 31, 2023 | -148.10 Mn |
| Sep 30, 2023 | 26.10 Mn |
| Jun 30, 2023 | 11.00 Mn |
| Mar 31, 2023 | -600,000.00 |
| Dec 31, 2022 | 8.80 Mn |
| Sep 30, 2022 | 3.90 Mn |
| Jun 30, 2022 | -10.90 Mn |
| Mar 31, 2022 | -6.20 Mn |
| Dec 31, 2021 | -273.90 Mn |
| Sep 30, 2021 | -9.40 Mn |
| Jun 30, 2021 | -23.00 Mn |